2-Nitro-tartranilsaeure | 339558-96-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-Nitro-tartranilsaeure
• 英文别名: d-2'-nitrotartranilic acid；(+)-2'-nitrotartranilic acid；Butanoic acid, 2,3-dihydroxy-4-[(nitrophenyl)amino]-4-oxo-；2,3-dihydroxy-4-(2-nitroanilino)-4-oxobutanoic acid
• CAS: 339558-96-2
• 化学式: C₁₀H₁₀N₂O₇
• 分子量: 270.199
• InChiKey: HTOIMXXCKYQKQM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.7
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  153
• 氢给体数：
  4
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  (1S,2R)-2-(2-chlorophenyl)-2-[4-[(4-methoxyphenyl)methyl]piperazin-1-yl]-1-phenylethanol;dihydrochloride 、 2-Nitro-tartranilsaeure 生成 (1S,2R)-2-(2-chlorophenyl)-2-[4-[(4-methoxyphenyl)methyl]piperazin-1-yl]-1-phenylethanol;2,3-dihydroxy-4-(2-nitroanilino)-4-oxobutanoic acid
  参考文献：
  名称：

  SHIMOKAWA NORIAKI; NAKAMURA HIDEO; SHIMAKAWA KEIKO; MINAMI HIDEO; NISHIMU+, J. MED. CHEM., 1979, 22, NO 1, 58-63

  摘要：

  DOI：

文献信息

• Pyrido [2,1-a] isoquinoline derivatives
  申请人：——

  公开号：US20040259903A1

  公开（公告）日：2004-12-23

  The present invention provides compounds of formula (I) 1 wherein R 1 , R 2 , R 3 and R 4 are as indicated in the description, or a pharmaceutically acceptable salt thereof. The compounds are useful for the treatment of diseases which are associated with DPP-IV, such as diabetes, particularly non-insulin dependent diabetes mellitus, and impaired glucose tolerance.

  本发明提供了式（I）的化合物，其中R1、R2、R3和R4如描述中所示，或其药学上可接受的盐。这些化合物可用于治疗与DPP-IV相关的疾病，如糖尿病，特别是非胰岛素依赖型糖尿病和糖耐量受损。
• [EN] PROCESS FOR THE PREPARATION OF RHO-KINASE INHIBITOR COMPOUNDS<br/>[FR] PROCESSUS DE PRÉPARATION DE COMPOSÉS INHIBITEURS DE RHO-KINASE
  申请人：INSPIRE PHARMACEUTICALS INC

  公开号：WO2009154940A1

  公开（公告）日：2009-12-23

  The present invention is directed to practical high-yielding synthetic processes to prepare compounds of general Formula III, IV, V, VII, VIII, IX, X, XII, XIV, and XV. Such compounds are useful as final products or can be used as intermediates and be further modified to prepare other desired products such as rho-kinase inhibitors. The present invention is also directed to certain novel compounds and/or novel solid forms of certain compounds.

  本发明旨在提供实用的高产率合成工艺，用于制备一般化学式III、IV、V、VII、VIII、IX、X、XII、XIV和XV的化合物。这些化合物可用作最终产品，也可用作中间体，并可进一步修改以制备其他所需产品，如rho-激酶抑制剂。本发明还涉及某些新颖化合物和/或某些化合物的新颖固体形式。
• Novel process
  申请人：——

  公开号：US20030004352A1

  公开（公告）日：2003-01-02

  A process for the manufacture of the (−) trans piperidine carbinol (1) by a process comprising contacting a racemic mixture of the piperidine carbinol in solution with (−)-ditoluoyltartaric acid, crystallising the (−) -ditoluoyltartaric acid salt of the piperidine carbinol, isolating the crystalline salt and neutralising the crystalline salt to regenerate the (−) trans isomer of the piperidine carbinol and the (−)-ditoluoyltartaric acid, which is characterised by one or more of the following steps: (1) combining solutions of the racemic piperidine carbinol and (−)-ditoluoyltartaric acid in acetone so that the combined solution contains 2-3 % wt/wt of water, (2) consolidating the chiral salt crystallisation at from 30 to 40° C., (3) cooling the crystallisation mixture to from 3 to 7° C. before isolating the chiral salt, (4) regenerating the (−) trans piperidine carbinol at a pH of from 10.5 to 11.5, (5) forming a concentrated solution of the (−) trans piperidine carbinol in toluene, contacting the solution with heptane at 60-65 ° C., and cooling stepwise to crystallise the (−) trans piperidine carbinol. Alternatively, a solution of the racemic piperidine carbinol in toluene, suitably from a previous stage in the manufacture of paroxetine, is combined with a solution of (−)- ditoluoyltartaic acid in acetone. The resultant (−) trans piperidine carbinol of structure (1) may be coupled with sesamol, then deprotected, to give paroxetine (2), with optional formation of a pharmaceutically acceptable salt of paroxetine.

  一种制备(−)反式哌啶羟甲醇（1）的方法，包括以下步骤：将哌啶羟甲醇的外消旋混合物溶解于溶液中，与(−)-二对甲苯酰酒石酸接触，结晶出哌啶羟甲醇的(−)-二对甲苯酰酸盐，分离结晶盐并将其中和以再生(−)反式异构体的哌啶羟甲醇和(−)-二对甲苯酰酒石酸。其中的特点包括以下一项或多项步骤：（1）将外消旋哌啶羟甲醇和(−)-二对甲苯酰酒石酸的溶液在丙酮中混合，使混合溶液含有2-3%重量/重量的水，（2）在30至40°C下进行手性盐结晶，（3）在分离手性盐之前将结晶混合物冷却至3至7°C，（4）在pH值为10.5至11.5下再生(−)反式哌啶羟甲醇，（5）在甲苯中形成(−)反式哌啶羟甲醇的浓缩溶液，将溶液与在60-65°C下的庚烷接触，逐步冷却以结晶(−)反式哌啶羟甲醇。另外，可以将在制备帕罗西汀的先前阶段合适地从甲苯中的外消旋哌啶羟甲醇的溶液与丙酮中的(−)-二对甲苯酰酒石酸的溶液结合。结果得到的结构为(1)的(−)反式哌啶羟甲醇可与芝麻酚偶联，然后去保护，得到帕罗西汀（2），并可选择形成帕罗西汀的药用可接受盐。
• L-tartrate of trans-(-)-4-(4-fluorophenyl)-3-hydroxymethylpiperidine compound and process for preparing the same
  申请人：Sumika Fine Chemicals Co., Ltd.

  公开号：US20020028944A1

  公开（公告）日：2002-03-07

  An L-tartrate of a trans-(−)-4-(4-fluorophenyl)-3-hydroxymethylpiperidine compound, represented by the formula (I): 1 wherein R 1 is hydrogen atom, a substituted or unsubstituted, linear or branched alkyl group having 1 to 6 carbon atoms, or an aralkyl group having 7 to 12 carbon atoms. The L-tartrate of trans-(−)-4-(4-fluorophenyl)-3-hydroxymethylpiperidine compound can be suitably used as an intermediate for pharmaceuticals such as paroxetine which is useful, for example, as an antidepressant.

  一种以式(I)所表示的反式-(−)-4-(4-氟苯基)-3-羟甲基哌啶化合物的L-酒石酸盐：其中R1是氢原子，具有1至6个碳原子的取代或未取代的直链或支链烷基，或具有7至12个碳原子的芳基烷基。反式-(−)-4-(4-氟苯基)-3-羟甲基哌啶化合物的L-酒石酸盐可适当用作制备药物的中间体，如帕罗西汀，例如作为抗抑郁剂。
• PROCESS FOR THE PREPARATION OF RHO-KINASE INHIBITOR COMPOUNDS
  申请人：She Jin

  公开号：US20100022775A1

  公开（公告）日：2010-01-28

  The present invention is directed to practical high-yielding synthetic processes to prepare compounds of general Formula III, IV, V, VII, VIII, IX, X, XII, XIV, and XV. Such compounds are useful as final products or can be used as intermediates and be further modified to prepare other desired products such as rho-kinase inhibitors. The present invention is also directed to certain novel compounds and/or novel solid forms of certain compounds.

  本发明涉及实用的高产率合成过程，用于制备通式III、IV、V、VII、VIII、IX、X、XII、XIV和XV的化合物。这些化合物可用作最终产品，也可用作中间体，并进一步改性以制备其他所需产品，如rho-激酶抑制剂。本发明还涉及某些新颖化合物和/或某些化合物的新颖固态形式。